Document is current
Any future updates will be listed below
-
Authors
King, Jordan A.
Walters, Noah
Rodrigues, Nadine
Al Bastami, Jenna
Mehri, Niki
Chan, Adrian
Spencer, Madison
Clark, Sadie
Ferrier, Evan
Orr, Serena L.
Rempel, Jocelyn
Hauenstein, Andreas
Roper, Joshua M.
Ralston, John D.
Peters, Ryan M.
-
Funding
Funding for this research was provided by:
Hotchkiss Brain Institute, University of Calgary
Neursantys
Natural Sciences and Engineering Research Council of Canada (RGPIN-2020-06068)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 9 September 2025
First Online: 31 October 2025
Declarations
:
: All procedures were approved by the University of Calgary Conjoint Health Research Ethics Board (Ethics ID: REB22-1006) prior to participant recruitment and retrospectively registered as a clinical trial on February 25, 2025 (NCT06846047). All participants provided written informed consent before participation.
: The authors give consent for publication.
: JDR, JR, and RMP have a commercial and financial interest in EVS therapeutics through their relationship with Neursantys Inc., which is pioneering novel wearable EVS devices.
